JP2017532961A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532961A5
JP2017532961A5 JP2017520449A JP2017520449A JP2017532961A5 JP 2017532961 A5 JP2017532961 A5 JP 2017532961A5 JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017532961 A5 JP2017532961 A5 JP 2017532961A5
Authority
JP
Japan
Prior art keywords
smad7
composition
antisense oligonucleotide
item
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017520449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532961A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/074066 external-priority patent/WO2016059239A1/en
Publication of JP2017532961A publication Critical patent/JP2017532961A/ja
Publication of JP2017532961A5 publication Critical patent/JP2017532961A5/ja
Pending legal-status Critical Current

Links

JP2017520449A 2014-10-17 2015-10-16 Smad7アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 Pending JP2017532961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
US62/065,598 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (2)

Publication Number Publication Date
JP2017532961A JP2017532961A (ja) 2017-11-09
JP2017532961A5 true JP2017532961A5 (enExample) 2018-11-29

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520449A Pending JP2017532961A (ja) 2014-10-17 2015-10-16 Smad7アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物

Country Status (12)

Country Link
US (2) US10337004B2 (enExample)
EP (1) EP3207136A1 (enExample)
JP (1) JP2017532961A (enExample)
KR (1) KR20170069262A (enExample)
CN (1) CN107406851A (enExample)
AU (1) AU2015332624A1 (enExample)
CA (1) CA2964667A1 (enExample)
EA (1) EA201790867A1 (enExample)
IL (1) IL251717A0 (enExample)
MA (1) MA43331A (enExample)
MX (1) MX2017004973A (enExample)
WO (1) WO2016059239A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
SI3121280T1 (sl) 2008-11-13 2025-08-29 Nogra Pharma Limited Antismiselne sestave in postopki za njihovo izdelavo ter uporabo
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗smad7治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CA2948411A1 (en) 2014-05-09 2015-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
JP2017537973A (ja) * 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してsmad7アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
KR20170069262A (ko) 2014-10-17 2017-06-20 노그라 파마 리미티드 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
WO2017147276A1 (en) 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition
JP2020503327A (ja) * 2016-12-30 2020-01-30 ノグラ ファーマ リミテッド Smad7アンチセンスオリゴヌクレオチドの組成物および乾癬を処置するまたは予防する方法
IL296562A (en) * 2020-04-24 2022-11-01 Nogra Pharma Ltd Compositions of smad7 antisense oligonucleotides (aso) and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
SI3121280T1 (sl) 2008-11-13 2025-08-29 Nogra Pharma Limited Antismiselne sestave in postopki za njihovo izdelavo ter uporabo
WO2010085151A2 (en) * 2009-01-26 2010-07-29 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
WO2011097644A2 (en) * 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗smad7治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
MX363746B (es) 2013-03-15 2019-04-01 Nogra Pharma Ltd Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CA2948411A1 (en) * 2014-05-09 2015-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2015011694A2 (en) 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
KR20170069262A (ko) 2014-10-17 2017-06-20 노그라 파마 리미티드 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してsmad7アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
CA3000195A1 (en) 2015-09-30 2017-04-06 Celgene Alpine Investment Company Ii, Llc Tlr modulators and methods of use
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてsmad7アンチセンスオリゴヌクレオチドを使用する方法

Similar Documents

Publication Publication Date Title
JP2017532961A5 (enExample)
Gane et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials
Jenner et al. Insights into host responses against pathogens from transcriptional profiling
AU2017224226A1 (en) Compositions and methods of using piRNAs in cancer diagnostics and therapeutics
CN102586408B (zh) 高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒
Truelove et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome
CN109414448A (zh) 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
US10337004B2 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
JP2017505623A5 (enExample)
FI3384049T3 (fi) Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
JP2018517704A5 (enExample)
CN101892311A (zh) 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒
BR112020020220A2 (pt) Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b
JP6612232B2 (ja) 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
Yao et al. Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics
Chen et al. CD55 variant associated with pegylated-interferon α therapy response in HBeAg-positive chronic hepatitis B patients
CN101892297B (zh) 高血压易感基因单核苷酸多态性位点的检测方法及其试剂盒
JP2005500029A5 (enExample)
JP2011193786A (ja) C型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット
CN105497900A (zh) 一种抗未分化甲状腺癌耐药靶点及其应用
CN110438262B (zh) 一种乙型肝炎病毒分型和耐药基因检测试剂盒
CN118265529A (zh) 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗
WO2025049568A1 (en) Treatment of muscle disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors
Wang Construction and analysis of competing endogenous RNA